Literature DB >> 19568177

Pharmacologically induced long QT type 2 can be rescued by activation of IKs with benzodiazepine R-L3 in isolated guinea pig cardiomyocytes.

Jakob Dahl Nissen1, Jonas Goldin Diness, Thomas Goldin Diness, Rie Schultz Hansen, Morten Grunnet, Thomas Jespersen.   

Abstract

The ionic current responsible for terminating the action potential (AP), and thereby in part determining the AP duration (APD), is the potassium current (IK), consisting of primarily two components: a rapidly (IKr) and a slowly (IKs) activating delayed rectifier potassium current. The aim of this study was to evaluate potential antiarrhythmic effects of compound induced IKs activation using the benzodiazepine L-364,373 (R-L3). Ventricular myocytes from guinea pigs were isolated and whole-cell current clamping was performed at 35 degrees C. It was found that 1 microM R-L3 significantly reduced the APD90 at pacing frequencies of 1, 2, and 4 Hz when compared to control (40 +/- 6%, 22 +/- 2%, and 32 +/- 2%, respectively). The reduction of APD90 was accompanied by a reduced triangulation (given as APD30-90) when compared to control at all pacing frequencies (62 +/- 7 ms vs. 41 +/- 3 ms, 55 +/- 5 ms vs. 35 +/- 6 ms, and 45 +/- 4 ms vs. 32 +/- 2 ms, at 1 Hz, 2 Hz, and 4 Hz, respectively). The abbreviated APDs also resulted in a reduction in the relative refractory period, and no direct protection against pacing induced early after-depolarizations (EAD) could be observed. However, an increase in repolarizing capacity was seen with 1 microM R-L3, as more complete repolarization of the AP was achieved before EADs could be elicited. Finally, a functional demonstration of the repolarization reserve revealed that increased IKs can counteract a pharmacologically reduced IKr. In conclusion, pharmacological activation of IKs possesses both pro- and antiarrhythmic characters. The most prominent antiarrhythmic propensity is the ability for IKs activation to rescue a cellular model of long QT type 2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568177     DOI: 10.1097/FJC.0b013e3181af6db3

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.

Authors:  Marek Malik
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 2.  Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.

Authors:  András Varró; István Baczkó
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

Authors:  Eunchong Hong; Sun Mi Gu; Jin Mook Kim; Kyung Sik Yoon; Jin-Moo Lee; Young-Hoon Kim; Soo Kyung Suh; Dohyun Lee; Heejong Eom; Jaesuk Yun; Hye Jin Cha
Journal:  Toxicol Res (Camb)       Date:  2022-07-08       Impact factor: 2.680

4.  Potassium channel activators differentially modulate the effect of sodium channel blockade on cardiac conduction.

Authors:  R Veeraraghavan; A P Larsen; N S Torres; M Grunnet; S Poelzing
Journal:  Acta Physiol (Oxf)       Date:  2012-09-14       Impact factor: 6.311

Review 5.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

6.  Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 Cardiomyocytes.

Authors:  Joseph R Stimers; Li Song; Nancy J Rusch; Sung W Rhee
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.